Minocycline protects against microgliopathy in a Csf1r haplo-insufficient mouse model of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)

Xin Li,Banglian Hu,Xiaoyan Guan,Ziwei Wang,Yuhang Zhou,Hao Sun,Xian Zhang,Yanfang Li,Xiaohua Huang,Yingjun Zhao,Xin Wang,Huaxi Xu,Yun-Wu Zhang,Zhanxiang Wang,Honghua Zheng
DOI: https://doi.org/10.1186/s12974-023-02774-1
IF: 9.3
2023-06-01
Journal of Neuroinflammation
Abstract:Mutations in colony-stimulating factor 1 receptor (CSF1R) are known to cause adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), which has been recently demonstrated as a primary microgliopathy characterized by cognitive impairment. Although the molecular mechanism underlying CSF1R-mediated microgliopathy remains unclear, therapeutic strategies have generally targeted modulation of microglial function. In particular, the microglial inhibitor, minocycline, has been shown to attenuate learning and memory deficits in several neurodegenerative diseases. The objectives of this study were to investigate the pathogenic mechanisms underlying ALSP and to explore the therapeutic effects of minocycline in an in vivo model of ALSP. We hypothesized that inhibiting microglial activation via minocycline could reverse the behavior and pathological defects in ALSP model mice.
immunology,neurosciences
What problem does this paper attempt to address?